Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with MDD.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• Outpatients.

• Sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article

• Subjects must have a primary diagnosis of major depressive disorder

Exclusion Criteria:

• Treatment with DVS-233 SR at any time in the past

• Treatment with venlafaxine (immediate release [IR] or ER) within 90 days of study day 1

• Known hypersensitivity to venlafaxine (IR or ER)